Skip to content

Effects of phrenic nerve magnetic stimulation on respiratory function in stroke patients

The effect and mechanism of phrenic nerve magnetic stimulation on pulmonary function in stroke patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075669
Enrollment
Unknown
Registered
2023-09-12
Start date
2023-09-13
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Magnetic stimulation group:Bilateral phrenic nerve magnetic stimulation of the neck
Regular rehabilitation training group:Regular rehabilitation training

Sponsors

The First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.The initial diagnosis of cerebral hemorrhage or infarction, as identified through imaging techniques such as cranial MRI or CT 2.Meet the diagnostic criteria for stroke as outlined in the 2015 Chinese Classification of Cerebrovascular Diseases. 3.Occurred within the preceding 0.5–6 months. 4.Able to comprehend and execute physician's orders, with a minimum score of 21 points on the Montreal Cognitive Assessment Scale. 5.Age: 18–70; sex: male or female. 6.Respiratory muscle weakness (= 70% of predicted maximal inspiratory pressure (MIP) and/or = 70% of maximal expiratory pressure (MEP) 7.The patient or his family members understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.History of pulmonary and thoracic-abdominal disease; 2.Combined myasthenia gravis or phrenic nerve paralysis; 3.History of malignant tumour or severe heart, liver, kidney or other vital organ disease. 4.Diagnosis of myocardial infarction within the past 3 months. 5.Severe lung disease, defined as severe chronic obstructive pulmonary disease (COPD), with oxygen saturation levels below 90% for COPD patients) or below 92% for other patients. 6.Presence of neurologic deficits other than stroke. 7.Facial paralysis affecting normal lip closure. 8.Experience of dizziness or nausea/vomiting during MIP testing. 9.Impaired level of consciousness or cognitive impairment. 10.Presence of any metallic foreign body in the neck or chest. 11.Presence of an implantable pacemaker. 12History of seizures.

Design outcomes

Primary

MeasureTime frame
maximal inspiratory pressure, MIP;maximal expiratory pressure, MEP;

Secondary

MeasureTime frame
lung function parameters;Diaphragm mobility and thickness;

Countries

China

Contacts

Public ContactXiaoli Xu

The First Affiliated Hospital of Fujian Medical University

2220730546@fjmu.edu.cn+86 158 8002 2670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026